KeyGene and GENALICE Join Forces
News Oct 30, 2013
KeyGene is an Agro-industrial Biotech company focusing on genomic research and technology development to accelerate crop improvement. Using cutting-edge molecular genetic technologies, such as next-generation sequencing, KeyGene has a leading and innovative role in this market. “The breakthrough software solution, GENALICE MAP, is a leap forward in improving our analysis pipeline and in staying ahead of competition. We tested, validated and now implemented MAP, as it immediately offers us major competitive advantages on speed and accuracy in DNA analysis. In addition, the strategic partnership with GENALICE allows us to influence new functionalities within the product that will benefit our business,” comments Arjen van Tunen, CEO of KeyGene”.
GENALICE is a young and innovative Dutch software company. In a worldwide online launching event it will present its first product to all DNA researchers in the world on 12/12 later this year. “This first commercial deal, even before the official launch of our product, shows the quality of our product and the need for GENALICE MAP in the field of DNA data processing.” says Hans Karten, CTO of GENALICE.
Jos Lunenberg, CEO of GENALICE, further comments: “We are extremely pleased with the partnership with KeyGene. It clearly shows that GENALICE MAP is highly welcomed in the field of plant genomics. Plant DNA is often far more complex than human DNA. This demonstrates that we are also well positioned to deal with complex variations in DNA, which is found in complex diseases such as cancer. On top of this, our product is up to 200 times faster than most commonly used tools and it reduces the data footprint significantly. This makes MAP, apart from the most accurate and fastest, also the most cost-effective solution in this market”.
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE